FindTrial
Sign In

A study on the short and long term outcomes of patients diagnosed with a fungal disease called Mucormycosis (commonly known as Black Fungus)

Incidence of adverse outcomes and risk factors for mortality among Mucormycosis patients in India: a multi-centric ambispective cohort study, 2021-2022

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2021/09/036254
Enrollment
480
Registered
2021-09-06
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B464- Disseminated mucormycosis Health Condition 2: B462- Gastrointestinal mucormycosis Health Condition 3: B460- Pulmonary mucormycosis Health Condition 4: B461- Rhinocerebral mucormycosis

Interventions

None listed

Sponsors

Dr Manickam P
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: - Mucormycosis patients admitted between 1st March 2021 and 31st July 2021 - Hospitalised for Mucormycosis in the study hospital

Exclusion criteria

Exclusion criteria: - Mucormycosis patients who could not be contacted despite two phone calls - Not available for follow-up during the study period

Design outcomes

Primary

MeasureTime frame
SurvivalTimepoint: 1, 3, 6, and 12 months—

Secondary

MeasureTime frame
DiabilityTimepoint: 1, 3, 6, and 12 months;Quality of Life (EQ-5D)Timepoint: 1, 3, 6, and 12 months—

Countries

India

Contacts

Public ContactManickam Ponnaiah

ICMR - National Institute of Epidemiology

manickam@nie.gov.in9444030527

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026